Innovating Works

SAF2012-40149-C02-01

Financiado
ESTUDIO PRECLINICO PARA EVALUAR CELULAS MESENQUIMALES HUMANAS DE PLACENTA QUE PR...
ESTUDIO PRECLINICO PARA EVALUAR CELULAS MESENQUIMALES HUMANAS DE PLACENTA QUE PROMUEVAN REGENERACION OSEA Y DESARROLLAR UN NUEVO PRODUCTO CELULAR BAJO CONDICIONES GMP CELL THERAPY TO FOSTER BONE REGENERATION IN COMPLEX SITUATIONS IS BEING CLINICALLY TESTED, FREQUENTLY BASED IN AUTOLOGOUS MESENCHYMAL STEM CELLS (MSCS). ALLOGENIC ALTERNATIVES IN CASE OF LIMITED OSTEOGENIC POTENTIAL (ELDERLY PATIE... CELL THERAPY TO FOSTER BONE REGENERATION IN COMPLEX SITUATIONS IS BEING CLINICALLY TESTED, FREQUENTLY BASED IN AUTOLOGOUS MESENCHYMAL STEM CELLS (MSCS). ALLOGENIC ALTERNATIVES IN CASE OF LIMITED OSTEOGENIC POTENTIAL (ELDERLY PATIENTS WITH OSTEOPOROTIC FRACTURES) ARE SCARCELY DEVELOPED. THIS PROPOSAL WILL PROVIDE PRECLINICAL STUDIES ON ADULT HUMAN DECIDUAL MESENCHYMAL STEM CELLS (DMSCS) TO SCREEN THEIR BEHAVIOUR AND INTERACTION IN SELECTIVE OSTEOINDUCTIVE MICROENVIRONMENTS WITH BIOMATERIALS IN CURRENT CLINICAL USE, IN ORDER TO ASCERTAIN THE OSTEOGENIC POTENTIAL OF THESE CELLS. IN VITRO (CELL CULTURE IN 2D AND 3D IN A BIOREACTOR) AND ANIMAL MODELS WILL HELP TO EXPLORE SAFETY ISSUES, INCLUDING CELL TRACING, AND TO EVALUATE THE ABILITY OF THESE CELLS TO FORM NEW BONE UPON IMPLANTATION. CELL PRODUCTION SCALING UNDER GMP CONDITIONS TOWARDS THE RELEASE OF A SAFE AND EFFICACIOUS INVESTIGATIONAL MEDICINAL PRODUCT (IMP) WILL BE DEVELOPED AND STANDARDIZED. THE FINAL PRODUCT WILL BE ASSESSED IN PRECLINICAL MODELS TO CONFIRM THE VIABILITY IN THE INTENDED APPLICATION. AN IMP DOCUMENT BASED ON THE RESULTS OF THE PROPOSED INVESTIGATION WILL ALLOW TO READILY INITIATE SUBSEQUENT EARLY PHASE CLINICAL TRIALS. ver más
01/01/2012
FUNDACIÓN PARA LA...
70K€
Perfil tecnológico estimado

Línea de financiación: concedida

El organismo AGENCIA ESTATAL DE INVESTIGACIÓN notifico la concesión del proyecto el día 2012-01-01
Presupuesto El presupuesto total del proyecto asciende a 70K€
Líder del proyecto
FUNDACIÓN PARA LA INVESTIGACIÓN BIOMÉDICA. HO... No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5 4M